64127-44-2

Basic information

• Product Name: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER
• Synonyms: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER;ETHYL 4-CYCLOHEXYL-3-OXOBUTANOATE;4-Cyclohexyl-3-oxobutanoic acid ethyl ester
• CAS NO: 64127-44-2
• Molecular Formula: C₁₂H₂₀O₃
• Molecular Weight: 212.29
• Mol File: 64127-44-2.mol

Chemical Properties

• Boiling Point: 292.336 °C at 760 mmHg
• Flash Point: 123.844 °C
• Appearance: /
• Density: 1.008 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.457
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER(64127-44-2)
• EPA Substance Registry System: 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER(64127-44-2)

Safety Data

• Hazardous Substances Data: 64127-44-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER is used as a synthetic intermediate for the development of pharmaceutical compounds, particularly for the creation of anti-inflammatory, analgesic, and anti-cancer drugs. Its role in the synthesis process is crucial, as it contributes to the formulation of effective medications that address a range of health conditions.
Used in Drug Synthesis:
As a building block in drug synthesis, 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER is utilized for its potential to be incorporated into the molecular structures of new and existing pharmaceuticals. This allows for the enhancement of drug properties, such as efficacy, solubility, and bioavailability, ultimately leading to improved therapeutic outcomes for patients.
Used in Research and Development:
In the realm of research and development, 4-CYCLOHEXYL-3-OXO-BUTYRIC ACID ETHYL ESTER serves as a valuable tool for scientists and chemists. It is employed in the exploration of new drug candidates and the optimization of existing drug formulations, contributing to the advancement of pharmaceutical science and innovation.

InChI:InChI=1/C12H20O3/c1-2-15-12(14)9-11(13)8-10-6-4-3-5-7-10/h10H,2-9H2,1H3

Upstream product

• 1007476-32-5 sodium ethyl acetylacetate enolate 
• 23860-35-7 cyclohexylacetic acid chloride 
• 2033-24-1 cycl-isopropylidene malonate 
• 64-17-5 ethanol 
• 5292-21-7 Cyclohexylacetic acid 
• 6148-64-7 ethyl potassium malonate 
• 141-78-6 ethyl acetate 
• 1071-46-1 hydrogen ethyl malonate 
• 103-78-6 4-cyclohexyl-butan-2-one 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 74632-02-3 5-Cyclohexyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid ethyl ester 
• 158779-34-1 3-N-allyl-6-cyclohexylmethyl-2-thiouracil 
• 1561959-88-3 4-chloro-5-(cyclohexylmethyl)-1-(2,6-di-tert-butylpyridin-4-yl)-N-((3-methyloxetan-3-yl)methyl)-1H-pyrazole-3-carboxamide 
• 349496-81-7 ethyl 5-(cyclohexylmethyl)-1H-pyrazole-3-carboxylate 
• 1561965-60-3 ethyl 5-(cyclohexylmethyl)-1-(2,6-di-tert-butylpyridin-4-yl)-1H-pyrazole-3-carboxylate 
• 1561965-63-6 ethyl 4-chloro-5-(cyclohexylmethyl)-1-(2,6-di-tert-butylpyridin-4-yl)-1H-pyrazole-3-carboxylate 
• 1561965-64-7 4-chloro-5-(cyclohexylmethyl)-1-(2,6-di-tert-butylpyridin-4-yl)-1H-pyrazole-3-carboxylic acid 
• 1561965-67-0 ethyl 5-(cyclohexylmethyl)-4-fluoro-1H-pyrazole-3-carboxylate 

Relevant articles and documents

Fungal Dioxygenase AsqJ Is Promiscuous and Bimodal: Substrate-Directed Formation of Quinolones versus Quinazolinones

Previous studies showed that the FeII/α-ketoglutarate dependent dioxygenase AsqJ induces a skeletal rearrangement in viridicatin biosynthesis in Aspergillus nidulans, generating a quinolone scaffold from benzo[1,4]diazepine-2,5-dione substrates. We report that AsqJ catalyzes an additional, entirely different reaction, simply by a change in substituent in the benzodiazepinedione substrate. This new mechanism is established by substrate screening, application of functional probes, and computational analysis. AsqJ excises H2CO from the heterocyclic ring structure of suitable benzo[1,4]diazepine-2,5-dione substrates to generate quinazolinones. This novel AsqJ catalysis pathway is governed by a single substituent within the complex substrate. This unique substrate-directed reactivity of AsqJ enables the targeted biocatalytic generation of either quinolones or quinazolinones, two alkaloid frameworks of exceptional biomedical relevance.

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

Affinity of 3-acyl substituted 4-quinolones at the benzodiazepine site of GABAA receptors

The finding that alkyl 1,4-dihydro-4-oxoquinoline-3-carboxylate and N-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxamide derivatives may be high-affinity ligands at the benzodiazepine binding site of the GABAA receptor, prompted a study of 3-acyl-1,4-dihydro-4-oxoquinoline (3-acyl-4-quinolones). In general, the affinity of the 3-acyl derivatives was found to be comparable with the 3-carboxylate and the 3-carboxamide derivatives, and certain substituents (e.g., benzyl) in position 6 were again shown to be important. As it is believed that the benzodiazepine binding site is situated between an α- and a γ-subunit in the GABAA receptor, selected compounds were tested on the α1β2γ2s, α2β2γ2s and α3β2γ2s GABAA receptor subtypes. The 3-acyl-4-quinolones display various degrees of selectivity for α1- versus α2- and α3-containing receptors, and high-affinity ligands essentially selective for α1 over α3 were developed.

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivity

Endothelins, ET-1, ET-2, and ET-3 are potent vasoconstricting and mitogenic 21-amino acid bicyclic peptides, which exert their effects upon binding to the ET(A) and ET(B) receptors. The ET(A) receptor mediates vasoconstriction and smooth muscle cell proliferation, and the ET(B) receptor mediates different effects in different tissues, including nitric oxide release from endothelial cells, and vasoconstriction in certain vascular cell types. Selective antagonists of endothelin receptor subtypes may prove useful in determining the role of endothelin in various tissue types and disease states, and hence as therapeutic agents for such diseases. The pyrrolidine carboxylic acid A-127722 has been disclosed as a potent and ET(A)-selective antagonist, and is currently undergoing clinical trials. In our efforts to find antagonists with altered selectivity (ET(A)-selective, ET(B)-selective, or nonselective), we investigated the SAR of the 2-substituent on the pyrrolidine. Compounds with alkyl groups at the 2-position possessed ET(A) selectivity improved over A-127722 (1400-fold selective), with the best of these compounds showing nearly 19,000-fold selectivity. Copyright (C) 1999 Elsevier Science Ltd.

Cyclization Reactions of Ethoxymethylenemalononitrile with 4-Substituted Acetoacetates

Base-catalyzed cyclization of ethoxymethylenemalononitrile 2 with substituted acetoacetates 1 a-c leads to the ethyl benzoates 3 a-c.Depending on the reaction conditions either ethyl 4-aminobenzoates 3 d-i or ethyl 4-(2,2-dicyanethylene)aminobenzoates 4 d-h are available from 2 and the 4-oxyacetoacetates 1 d-i.The preparation of the acetoacetates 1 a-c and 1 g-i is also described. - Keywords: Ethoxymethylenemalononitrile; Cyclization; Ethyl benzoates